[1]
M. Veltkamp, M. Drent, and R. P. Baughman, “Infliximab or biosimilars in sarcoidosis; to switch or not to switch?”, Sarcoidosis VDLD, vol. 32, no. 4, pp. 280–283, Jan. 2016.